Zoetis stock is trading -14.97% below its average target price of $194.41 after dropping -2.8% during today's morning session. Analysts are giving the Large-Cap Pharmaceutical company an average rating of buy and target prices ranging from $165.0 to $238.0 per share.
The stock has an average amount of shares sold short at 2.3%, and a short ratio of 3.2. The company's insiders own 0.23% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 96.5% of Zoetis's shares being owned by this investor type.
Institutions Invested in Zoetis
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-03-31 | Vanguard Group Inc | 9% | 41,556,164 | $6,869,234,036 |
| 2025-03-31 | Blackrock Inc. | 9% | 38,482,557 | $6,361,166,789 |
| 2025-03-31 | State Street Corporation | 4% | 19,796,791 | $3,272,409,612 |
| 2025-03-31 | State Farm Mutual Automobile Insurance Co | 4% | 15,892,903 | $2,627,096,914 |
| 2025-03-31 | Morgan Stanley | 3% | 12,746,043 | $2,106,920,946 |
| 2025-03-31 | Geode Capital Management, LLC | 2% | 10,986,007 | $1,815,986,990 |
| 2025-03-31 | Alliancebernstein L.P. | 2% | 10,856,391 | $1,794,561,465 |
| 2025-03-31 | Polen Capital Management, LLC | 2% | 8,796,847 | $1,454,118,835 |
| 2025-03-31 | Bank of America Corporation | 2% | 7,329,544 | $1,211,573,645 |
| 2025-03-31 | Northern Trust Corporation | 1% | 6,504,902 | $1,075,260,320 |
Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Zoetis.
